{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T14:14:25Z","timestamp":1791728065483,"version":"4.3.4"},"reference-count":106,"publisher":"SAGE Publications","issue":"2_suppl","license":[{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Toxicol"],"published-print":{"date-parts":[[2008,3]]},"abstract":"<jats:p>Poloxamers are polyoxyethlyene, polyoxypropylene block polymers. The impurities of commercial grade Poloxamer 188, as an example, include low-molecular-weight substances (aldehydes and both formic and acetic acids), as well as 1,4-dioxane and residual ethylene oxide and propylene oxide. Most Poloxamers function in cosmetics as surfactants, emulsifying agents, cleansing agents, and\/or solubilizing agents, and are used in 141 cosmetic products at concentrations from 0.005% to 20%. Poloxamers injected intravenously in animals are rapidly excreted in the urine, with some accumulation in lung, liver, brain, and kidney tissue. In humans, the plasma concentration of Poloxamer 188 (given intravenously) reached a maximum at 1 h, then reached a steady state. Poloxamers generally were ineffective in wound healing, but were effective in reducing postsurgical adhesions in several test systems. Poloxamers can cause hypercholesterolemia and hypertriglyceridemia in animals, but overall, they are relatively nontoxic to animals, with LD50 values reported from 5 to 34.6 g\/kg. Short-term intravenous doses up to 4 g\/kg of Poloxamer 108 produced no change in body weights, but did result in diffuse hepatocellular vacuolization, renal tubular dilation in kidneys, and dose-dependent vacuolization of epithelial cells in the proximal convoluted tubules. A short-term inhalation toxicity study of Poloxamer 101 at 97 mg\/m3 identified slight alveolitis after 2 weeks of exposure, which subsided in the 2-week postexposure observation period. A short-term dermal tox-icity study of Poloxamer 184 in rabbits at doses up to 1000 mg\/kg produced slight erythema and slight intradermal inflammatory response on histological examination, but no dose-dependent body weight, hematology, blood chemistry, ororgan weight changes. A6-month feeding study in rats and dogs of Poloxamer 188 at exposures up to 5% in the diet produced no adverse effects. Likewise, Poloxamer 331 (tested up to 0.5 g\/kg day-1), Poloxamer 235 (tested up to 1.0 g\/kg day-1), and Poloxamer 338 (at 0.2 or 1.0 g\/kg day-1) produced no adverse effects in dogs. Poloxamer 338 (at 5.0 g\/kg day-1) produced slight transient diarrhea in dogs. Poloxamer 188 at levels up to 7.5% in diet given to rats in a 2-year feeding study produced diarrhea at 5% and 7.5% levels, a small decrease in growth at the 7.5% level, but no change in survival. Doses up to 0.5 mg\/kg day-1 for 2 years using rats produced yellow discoloration of the serum, high serum alkaline phosphatase activity, and elevated serum glutamicpyruvic transaminase and glutamic-oxalacetic transaminase activities. Poloxamers are minimal ocular irritants, but are not dermal irritants or sensitizers in animals. Data on reproductive and developmental toxicity of Poloxamers were not found. An Ames test did not identify any mutagenic activity of Poloxamer 407, with or without metabolic activation. Several studies have suggested anti-carcinogenic effects of Poloxamers. Poloxamers appear to increase the sensitivity to anticancer drugs of multidrug-resistant cancer cells. In clinical testing, Poloxamer 188 increased the hydration of feces when used in combination with a bulk laxative treatment. Compared to controls, one study of angioplasty patients receiving Poloxamer 188 found a reduced myocardial infarct size and a reduced incidence of reinfarction, with no evidence of toxicity, but two other studies found no effect. Poloxamer 188 given to patients suffering from sickle cell disease had decreased pain and decreased hospitilization, compared to controls. Clinical tests of dermal irritation and sensitization were uniformly negative. The Cosmetic Ingredient Review (CIR) Expert Panel stressed that the cosmetic industry should continue to use the necessary purification procedures to keep the levels below established limits for ethylene oxide, propylene oxide, and 1,4-dioxane. The Panel did note the absence of reproductive and developmental toxicity data, but, based on molecular weight and solubility, there should be little skin penetration and any penetration of the skin should be slow. Also, the available data demonstrate that Poloxamers that are introduced into the body via routes other than dermal exposure have a rapid clearance from the body, suggesting that there would be no risk of reproductive and\/or developmental toxicity. Overall, the available data do not suggest any concern about carcinogenesis. Although there are gaps in knowledge about product use, the overall information available on the types of products in which these ingredients are used, and at what concentration, indicates a pattern of use. Based on these safety test data and the information that the manufacturing process can be controlled to limit unwanted impurities, the Panel concluded that these Poloxamers are safe as used.<\/jats:p>","DOI":"10.1080\/10915810802244595","type":"journal-article","created":{"date-parts":[[2008,10,2]],"date-time":"2008-10-02T02:49:31Z","timestamp":1222915771000},"page":"93-128","source":"Crossref","is-referenced-by-count":143,"title":["Safety Assessment of Poloxamers 101, 105, 108, 122, 123, 124, 181, 182, 183, 184, 185, 188, 212, 215, 217, 231, 234, 235, 237, 238, 282, 284, 288, 331, 333, 334, 335, 338, 401, 402, 403, and 407, Poloxamer 105 Benzoate, and Poloxamer 182 Dibenzoate as Used in Cosmetics"],"prefix":"10.1177","volume":"27","member":"179","published-online":{"date-parts":[[2008,8]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.5.2041"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0927-7765(99)00064-8"},{"key":"e_1_2_1_4_1","doi-asserted-by":"crossref","unstructured":"Anonymous. 1997. Featured excipient: Poloxamer. Int. J. Pharm. Compound 1:190-191.","DOI":"10.3928\/1081-597X-19970301-23"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(95)00134-D"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/0006355X2001038002003004"},{"key":"e_1_2_1_7_1","unstructured":"BASF. 2002. Technical Bulletin: Pluronic Block Copolymer NF Grades (Poloxamer NF Grades)."},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1018942823676"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.043307"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3565(24)29254-5"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3565(24)38781-6"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2001.2165"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1989.tb06555.x"},{"key":"e_1_2_1_14_1","first-page":"L261","article-title":"Dose-dependent hyperlipidemia in rabbits following administration of Poloxamer 407 gel.","volume":"65","year":"1999","unstructured":"Blonder, J. M., L. Baird, J. C. Fulfs, and G. J. Rosenthal. 1999.Dose-dependent hyperlipidemia in rabbits following administration of Poloxamer 407 gel.Life Sci.65:L261.","journal-title":"Life Sci."},{"key":"e_1_2_1_15_1","first-page":"24","article-title":"Repair of porcine full-thickness skin defects with autologous tissue engineered skin.","volume":"40","year":"2002","unstructured":"Cao, Y., X. Cai, L. Cui, Q. Shang, W. Liu, and W. Guan. 2002.Repair of porcine full-thickness skin defects with autologous tissue engineered skin.Zhonghua. Wai. Re. Za. Zhi.40:24\u201326 [translated from Chinese].","journal-title":"Zhonghua. Wai. Re. Za. Zhi."},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1163\/156856298X00578"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-199603000-00001"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1646460"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01024566"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.102.3.533"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1101\/lm.6.6.634"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.20.9.1241"},{"key":"e_1_2_1_23_1","unstructured":"Collaborative Organization for RheothRx Evaluation (CORE). 1997. Effects of RheothRx on mortality morbidity left ventricular function and infarct size in patients with acute myocardial infarction. Collaborative Organization for RhethRx Evaluation (CORE). Circulation 96:192-201."},{"key":"e_1_2_1_24_1","first-page":"33","article-title":"Antiobesity activity of pluronic L-101.","volume":"4","year":"1980","unstructured":"Comai, R., and A. C. Sullivan. 1980.Antiobesity activity of pluronic L-101.Int. J. Obesity4: 33\u201342.","journal-title":"Int. J. Obesity"},{"key":"e_1_2_1_25_1","unstructured":"Committee of Revision of the United States Pharmacopeial Convention. 1995. The United States Pharmacopeia 18th ed. 2279-2281. Rockville MD: United States Pharmacopeial Convention."},{"key":"e_1_2_1_26_1","first-page":"93","article-title":"Comparison of combination of ispaghula\/poloxamer 188 and placebo on gastrointestinal transit time.","volume":"75","year":"1982","unstructured":"Connaughton, J., and C. F. McCarthy. 1982.Comparison of combination of ispaghula\/poloxamer 188 and placebo on gastrointestinal transit time.I r. Med. J.75: 93\u201394.","journal-title":"I r. Med. J."},{"key":"e_1_2_1_27_1","unstructured":"Consumer Product Testing Company. 1990. Primary dermal and ocular irritation in rabbits of FINSOLV PL-62 (Poloxamer 182 Dibenzoate). 16 pages."},{"key":"e_1_2_1_28_1","unstructured":"Consumer Product Testing Company. 1992. Primary dermal and ocular irritation in rabbits of FINSOLV PL-355 (Poloxamer 105 Benzoate). 16 pages."},{"key":"e_1_2_1_29_1","unstructured":"Cosmetic Toiletry and Fragrance Association (CTFA). 2004a. Current concentration of use of Poloxamers. Unpublished data submitted by CTFA. 2 pages."},{"key":"e_1_2_1_30_1","unstructured":"CTFA. 2004b. Single insult patch test of Poloxamer 184 in rabbits. Unpublished data submitted by CTFA. 1 page."},{"key":"e_1_2_1_31_1","unstructured":"CTFA. 2004c. Safety evaluation of Poloxamer 184: Four week subacute dermal toxicity study in rabbits. Unpublished data submitted by CTFA. 7 pages."},{"key":"e_1_2_1_32_1","unstructured":"CTFA. 2004d. Allergic contact sensitization test: Moisturizing cleanser containing 5% Poloxamer 184. Unpublished data submitted by CTFA. 8 pages."},{"key":"e_1_2_1_33_1","unstructured":"CTFA. 2004e. An evaluation of the allergy potential of Poloxamer 185: Guinea pig maximization procedure. Unpublished data submitted by CTFA. 6 pages."},{"key":"e_1_2_1_34_1","unstructured":"CTFA. 2004f. Allergic contact sensitization test: Peel-off mask containing 5% Poloxamer 185. Unpublished data submitted by CTFA. 8 pages."},{"key":"e_1_2_1_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/00006982-199010000-00013"},{"key":"e_1_2_1_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0196-0644(05)82484-9"},{"key":"e_1_2_1_37_1","doi-asserted-by":"publisher","DOI":"10.3109\/10731199909117691"},{"key":"e_1_2_1_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(96)00025-4"},{"key":"e_1_2_1_39_1","doi-asserted-by":"publisher","DOI":"10.3109\/10731199809117464"},{"key":"e_1_2_1_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00172813"},{"key":"e_1_2_1_41_1","first-page":"47","article-title":"In vitro and in vivo evaluation of Pluronic F127-based ocular delivery system for timolol maleate.","volume":"241","year":"2002","unstructured":"El-Kamel, A. H.2002.In vitro and in vivo evaluation of Pluronic F127-based ocular delivery system for timolol maleate.J. Pharm.241: 47\u201355.","journal-title":"J. Pharm."},{"key":"e_1_2_1_42_1","doi-asserted-by":"publisher","DOI":"10.3109\/08941939609012466"},{"key":"e_1_2_1_43_1","unstructured":"Food and Drug Administration (FDA). 2002. Frequency of use of cosmetic ingredients. FDA Database. Washington DC: FDA."},{"key":"e_1_2_1_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4684-8181-5_35"},{"key":"e_1_2_1_45_1","volume-title":"International Cosmetic Ingredient Dictionary and Handbook","year":"2004","unstructured":"Gottschalck, T. E., and G. N. McEwen, Jr. eds. 2004.International Cosmetic Ingredient Dictionary and Handbook, 10th ed.Washington, DC: CTFA."},{"key":"e_1_2_1_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.297"},{"key":"e_1_2_1_47_1","doi-asserted-by":"publisher","DOI":"10.2166\/wst.1999.0362"},{"key":"e_1_2_1_48_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.12.2754"},{"key":"e_1_2_1_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/0735-6757(93)90106-L"},{"key":"e_1_2_1_50_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.2.435"},{"key":"e_1_2_1_51_1","unstructured":"Ivy Laboratories. 1993. Evaluation of the contact-sensitizing potential of a test agent eye lotion containing 8.0% Poloxamer 185. Unpublished data submitted by CTFA. 10 pages."},{"key":"e_1_2_1_52_1","unstructured":"Ivy Laboratories. 2003. An evaluation of the contact-sensitization potential of a topical coded product (facial cleanser with 3% Poloxamer 184) in human skin by means of the maximization assay. Unpublished data submitted by CTFA. 10 pages."},{"key":"e_1_2_1_53_1","doi-asserted-by":"publisher","DOI":"10.1021\/js960491e"},{"key":"e_1_2_1_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/0378-5173(93)90103-M"},{"key":"e_1_2_1_55_1","first-page":"83","article-title":"Toxicological evaluation of poloxamer vehicles for intramuscular use.","volume":"39","year":"1985","unstructured":"Johnston, T. P., and S. C. Miller. 1985.Toxicological evaluation of poloxamer vehicles for intramuscular use.J. Parenter. Sci. Technol.39: 83\u201389.","journal-title":"J. Parenter. Sci. Technol."},{"key":"e_1_2_1_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(93)90668-M"},{"key":"e_1_2_1_57_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199705000-00003"},{"issue":"3","key":"e_1_2_1_58_1","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/0002-8703(91)90510-O","article-title":"Reduction of myocardial infarct size by poloxamer 188 and mannitol in a canine model.","volume":"122","year":"1991","unstructured":"Justicz, A. G., W. V. Farnsworth, M. S. Soberman, et al. 1991.Reduction of myocardial infarct size by poloxamer 188 and mannitol in a canine model.Am. Heart J.122(3 Pt 1):671\u2013680.","journal-title":"Am. Heart J."},{"key":"e_1_2_1_59_1","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v19.i1.10"},{"key":"e_1_2_1_60_1","doi-asserted-by":"publisher","DOI":"10.3109\/01480549509017856"},{"key":"e_1_2_1_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0886-3350(88)80123-8"},{"issue":"3","key":"e_1_2_1_62_1","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1042\/BA20020123","article-title":"Effect of pluronic-block copolymers on the reduction of serummediated inhibition of gene transfer of polyethyleneimine-DNA complexes.","volume":"37","year":"2003","unstructured":"Kuo, J. H.2003.Effect of pluronic-block copolymers on the reduction of serummediated inhibition of gene transfer of polyethyleneimine-DNA complexes.Biotechnol. Appl. Biochem.37(Pt 3): 267\u2013271.","journal-title":"Biotechnol. Appl. Biochem."},{"key":"e_1_2_1_63_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1988.28488265271.x"},{"key":"e_1_2_1_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(90)90044-8"},{"key":"e_1_2_1_65_1","first-page":"48","article-title":"Toxicology of some non-ionic surfactants.","volume":"43","year":"1967","unstructured":"Leaf, C. W.1967.Toxicology of some non-ionic surfactants.Soap Chem. Spec.43:48.","journal-title":"Soap Chem. Spec."},{"key":"e_1_2_1_66_1","first-page":"31","article-title":"The non-ionic surfactant Polox-amer 188 (RheothRx) increases plasma and whole blood viscosity.","volume":"18","year":"1998","unstructured":"Lechmann, T., and W. H. Reinhart. 1998.The non-ionic surfactant Polox-amer 188 (RheothRx) increases plasma and whole blood viscosity.Clin. Hemorheol. Microcirc.18: 31\u201336.","journal-title":"Clin. Hemorheol. Microcirc."},{"key":"e_1_2_1_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/0731-7085(95)01621-X"},{"key":"e_1_2_1_68_1","first-page":"111","article-title":"Acute toxicity test of a new pharmaceutical adjuvant: Poloxamer 407.","volume":"9","year":"1998","unstructured":"Li, B., Y. J. Wang, C. Q. Ling, and W. J. Wang. 1998.Acute toxicity test of a new pharmaceutical adjuvant: Poloxamer 407.J. Chin. Pharm.9:111\u2013112 [translated from Chinese].","journal-title":"J. Chin. Pharm."},{"key":"e_1_2_1_69_1","doi-asserted-by":"publisher","DOI":"10.1097\/00019501-199609000-00008"},{"key":"e_1_2_1_70_1","doi-asserted-by":"publisher","DOI":"10.3109\/10731199509117673"},{"key":"e_1_2_1_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/0378-4274(86)90156-6"},{"key":"e_1_2_1_72_1","doi-asserted-by":"publisher","DOI":"10.1002\/em.2860090310"},{"key":"e_1_2_1_73_1","first-page":"302","article-title":"Effects of poloxamer 188 in a rabbit model of hemorrhagic shock.","volume":"24","year":"1994","unstructured":"Mayer, D. C., S. J. Strada, C. Hoff, R. L. Hunter, and M. Artman. 1994.Effects of poloxamer 188 in a rabbit model of hemorrhagic shock.Ann. Clin. Lab. Sci.24: 302\u2013311.","journal-title":"Ann. Clin. Lab. Sci."},{"issue":"5","key":"e_1_2_1_74_1","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0002-8703(98)70037-7","article-title":"Randomized, controlled trial of RheothRx (poloxamer 188) in patients with suspected acute myocardial infarction. RheothRx in Myocardial Infarction Study Group.","volume":"135","year":"1998","unstructured":"Maynard, C., R. Swenson, and J. A. Paris. 1998.Randomized, controlled trial of RheothRx (poloxamer 188) in patients with suspected acute myocardial infarction. RheothRx in Myocardial Infarction Study Group.Am. Heart J.135(5 Pt 1):797\u2013804.","journal-title":"Am. Heart J."},{"key":"e_1_2_1_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5223(19)34879-2"},{"key":"e_1_2_1_76_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1018873702411"},{"key":"e_1_2_1_77_1","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.2.1.11-13.1975"},{"key":"e_1_2_1_78_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/88.11.766"},{"key":"e_1_2_1_79_1","first-page":"412","article-title":"Poloxamers and poloxamines in nanoparticle engineering and experimental medicine.","volume":"184","year":"2000","unstructured":"Moghimi, S. M., and A. C. Hunter. 2000.Poloxamers and poloxamines in nanoparticle engineering and experimental medicine.Trends Biotechnol.184:412.","journal-title":"Trends Biotechnol."},{"key":"e_1_2_1_80_1","doi-asserted-by":"publisher","DOI":"10.1021\/bp00005a012"},{"key":"e_1_2_1_81_1","doi-asserted-by":"publisher","DOI":"10.1089\/lps.1993.3.187"},{"key":"e_1_2_1_82_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbm.820210907"},{"key":"e_1_2_1_83_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1996.tb02912.x"},{"key":"e_1_2_1_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(96)00414-6"},{"key":"e_1_2_1_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(97)00193-7"},{"key":"e_1_2_1_86_1","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2000.1540"},{"key":"e_1_2_1_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/0041-008X(78)90200-4"},{"key":"e_1_2_1_88_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbm.820280304"},{"key":"e_1_2_1_89_1","doi-asserted-by":"publisher","DOI":"10.1159\/000120740"},{"key":"e_1_2_1_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(16)55879-8"},{"key":"e_1_2_1_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9610(76)90293-2"},{"key":"e_1_2_1_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0196-0644(80)80228-9"},{"key":"e_1_2_1_93_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.90.6.2964"},{"key":"e_1_2_1_94_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.94.3.298"},{"key":"e_1_2_1_95_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1994.tb30437.x"},{"key":"e_1_2_1_96_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197201)29:1<171::AID-CNCR2820290126>3.0.CO;2-A"},{"key":"e_1_2_1_97_1","first-page":"48","article-title":"Poloxamer 407 as an intraperitoneal barrier material for the prevention of postsurgical adhesion formation and reformation in rodent models for reproductive surgery.","volume":"77","year":"1991","unstructured":"Steinleitner, A., H. Lamber, C. Kazensky, and B. Cantor. 1991.Poloxamer 407 as an intraperitoneal barrier material for the prevention of postsurgical adhesion formation and reformation in rodent models for reproductive surgery.Obstet. Gynecol.77: 48\u201352.","journal-title":"Obstet. Gynecol."},{"key":"e_1_2_1_98_1","doi-asserted-by":"publisher","DOI":"10.1177\/0006355X2000037004003"},{"key":"e_1_2_1_99_1","first-page":"269","article-title":"Two-week aerosol inhalation study in rats of ethylene oxide\/propylene oxide copolymers.","volume":"15","year":"1992","unstructured":"Ulrich, C. E., R. G. Geil, T. R. Tyler, G. L. Kennedy, and H. A. Birnbaum. 1992.Two-week aerosol inhalation study in rats of ethylene oxide\/propylene oxide copolymers.Drug Chem. Toxicol.15: 269\u2013270.","journal-title":"Drug Chem. Toxicol."},{"key":"e_1_2_1_100_1","unstructured":"United States Pharmacopeia The National Formulary (USP National Formulary) 2004. Poloxamer entry. pp. 2908-2909. Rockville MD: US Pharmacopeial Convention Inc."},{"key":"e_1_2_1_101_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.1998.9.7-1013"},{"key":"e_1_2_1_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022-4804(76)90082-2"},{"key":"e_1_2_1_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-9556(25)05778-2"},{"key":"e_1_2_1_104_1","doi-asserted-by":"publisher","DOI":"10.1016\/0142-9612(95)93579-3"},{"key":"e_1_2_1_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022-4804(78)90130-0"},{"key":"e_1_2_1_106_1","first-page":"192","article-title":"Poloxamer 407-mediated changes in plasma cholesterol and triglycerides following intraperitoneal injection to rats.","volume":"46","year":"1992","unstructured":"Wout, Z. G., E. A. Pec, J. A. Maggiore, R. H. Williams, P. Palicharla, and T. P. Johnston. 1992.Poloxamer 407-mediated changes in plasma cholesterol and triglycerides following intraperitoneal injection to rats.J. Parenter. Sci. Technol.46: 192\u2013200.","journal-title":"J. Parenter. Sci. Technol."},{"key":"e_1_2_1_107_1","first-page":"537","article-title":"Effect of fluorocarbon blood substitute on neutrophil phagocytic function.","volume":"10","year":"1989","unstructured":"Xiao, N., X. C. Lu, H. S. Chen, Z. H. Yang, and K. L. Tian. 1989.Effect of fluorocarbon blood substitute on neutrophil phagocytic function.Zhongguo. Yao. Li. Xue. Bao.10: 537\u2013539.","journal-title":"Zhongguo. Yao. Li. Xue. Bao."}],"container-title":["International Journal of Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1080\/10915810802244595","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1080\/10915810802244595","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:22:51Z","timestamp":1777458171000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1080\/10915810802244595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":106,"journal-issue":{"issue":"2_suppl","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["10.1080\/10915810802244595"],"URL":"https:\/\/doi.org\/10.1080\/10915810802244595","relation":{},"ISSN":["1091-5818","1092-874X"],"issn-type":[{"value":"1091-5818","type":"print"},{"value":"1092-874X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3]]}}}